Telix Pharmaceuticals | TLX - Equity Capital And Reserves


Telix Pharmaceuticals reported AUD408.17M in Equity Capital and Reserves for its fiscal semester ending in June of 2026.





Equity Capital And Reserves Change Date
Cochlear AUD 1.94B 12.2M Dec/2025
CSL USD 18.66B 2.75B Dec/2025
Integral Diagnostics AUD 301.71M 1.33M Jun/2024
Mayne Pharma AUD 454.19M 93.58M Jun/2024
Medical Developments International AUD 54.77M 335K Dec/2025
Mesoblast USD 568.4M 6.28M Jun/2026
Neuren Pharmaceuticals AUD 338.45M 15.18M Dec/2025
Pacific Edge NZD 10.66M 16.24M Jun/2026
Paradigm Biopharmaceuticals AUD 6M 15.18M Dec/2025
Polynovo AUD 83.14M 121K Dec/2025
PYC Therapeutics AUD 147.18M 22.82M Dec/2025
Ramsay Health Care AUD 4.79B 916.1M Dec/2025
ResMed USD 6.49B 171.03M Mar/2026
Sonic Healthcare AUD 8.2B 120.9M Dec/2024